Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.66 |
| ▸ | HTR7 | P34969 | 5/20 | 0.66 |
| ▸ | DRD2 | P14416 | 5/20 | 0.66 |
| ▸ | HTR2A | P28223 | 3/20 | 0.66 |
| ▸ | HTR6 | P50406 | 3/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.66 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.66 |
| ▸ | HTR1D | P28221 | 4/20 | 0.60 |
| ▸ | HTR1B | P28222 | 3/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7255624 | 0.88 | ADRA1D (0.83) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL8557344 | 0.87 | HTR1A (0.76) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL8877428 | 0.86 | OPRM1 (0.67) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL8557097 | 0.86 | HTR1A (0.70) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL5389005 | 0.85 | HTR1D (0.63) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL8557700 | 0.84 | MPO (0.71) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL5385305 | 0.84 | DRD2 (0.65) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL11039326 | 0.84 | ADRA1D (0.77) | SLC6A4ADRA1D | |
| SCHEMBL5389529 | 0.83 | HTR1D (0.66) | HTR1ASLC6A4HTR7DRD2HTR2A | |
| SCHEMBL5380987 | 0.82 | OPRM1 (0.62) | HTR1ASLC6A4HTR7DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4463455-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Suven Life Sciences Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | GRIN2C, SLC1A2, CNR2 | HTR1A 127/4885SLC6A4 60/4885HTR7 245/4885 |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GRIN2C, CNR2, INA | HTR1A 183/4885SLC6A4 63/4885HTR7 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.